Skip to main content

Peer Review reports

From: Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Original Submission
24 Dec 2013 Submitted Original manuscript
24 Feb 2014 Author responded Author comments - John Souglakos
4 Feb 2014 Reviewed Reviewer Report - Wataru Ichikawa
17 Feb 2014 Reviewed Reviewer Report - Sook-Ryun Park
Resubmission - Version 2
24 Feb 2014 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
1 Apr 2014 Author responded Author comments - John Souglakos
6 Mar 2014 Reviewed Reviewer Report - Wataru Ichikawa
19 Mar 2014 Reviewed Reviewer Report - Sook-Ryun Park
Resubmission - Version 4
1 Apr 2014 Submitted Manuscript version 4
9 Apr 2014 Author responded Author comments - John Souglakos
Resubmission - Version 5
9 Apr 2014 Submitted Manuscript version 5
Publishing
16 Apr 2014 Editorially accepted
22 Apr 2014 Article published 10.1186/1471-2407-14-277

You can find further information about peer review here.

Back to article page